Effect of intravenous administration of cibenzoline on left ventricular diastolic pressures in patients with hypertrophic cardiomyopathy - Its relationship to transmitral doppler flow profiles

Circulation Journal

Volumn 71, Issue 10, 2007, Pages 1540-1544

  Hamada, Mareomi ^a   Aono, Jun ^a   Ikeda, Shuntaro ^a   Watanabe, Kouki ^a   Inaba, Shinji ^b   Suzuki, Jun ^b   Ohtsuka, Tomoaki ^b   Shigematsu, Yuji ^b  

^a Uwajima City Hospital   (Japan)

^b EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antiarrhythmia agents; Cibenzoline; Hypertrophic cardiomyopathy; Left ventricular diastolic pressures; Transmitral Doppler velocity

Indexed keywords

CIBENZOLINE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOPPLER FLOWMETER; DRUG BLOOD LEVEL; DRUG EFFECT; HUMAN; HYPERTROPHIC CARDIOMYOPATHY;

AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL NATRIURETIC FACTOR; BLOOD PRESSURE; CARDIOMYOPATHY, HYPERTROPHIC; CATECHOLAMINES; FEMALE; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; LASER-DOPPLER FLOWMETRY; MALE; MIDDLE AGED; VENTRICULAR DYSFUNCTION, LEFT;

EID: 34948861765     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.71.1540     Document Type: Article

References (26)

1. Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, Aeppli DM. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 1999; 281: 650-655.
2. Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003; 348: 295-303.
3. Pollick C. Muscular subaortic stenosis: Hemodynamic and clinical improvement after disopyramide. N Engl J Med 1982; 307: 997-999.
4. Sherrid M, Deria E, Dwyer E. Oral disopyramide therapy for obstructive hypertrophic cardiomyopathy. Am J Cardiol 1988; 62: 1085-1088.
5. Pollick C, Kimball B, Henderson M, Wigle ED. Disopyramide in hypertrophic cardiomyopathy. I: Hemodynamic assessment after intravenous administration. Am J Cardiol 1988; 62: 1248-1251.
6. Kimball BP, Bui S, Wigle ED. Acute dose-response effects of intravenous disopyramide in hypertrophic obstructive cardiomyopathy. Am Heart J 1993; 125: 1691-1697.
7. Hamada M, Shigematsu Y, Ikeda S, Hara Y, Okayama H, Kodama K, et al. Class Ia antiarrhythmic drug cibenzoline: A new approach to the medical treatment of hypertrophic obstructive cardiomyopathy. Circulation 1997; 96: 1520-1524.
8. Hamada M, Shigematsu Y, Inaba S, Aono J, Ikeda S, Watanabe K, et al. Antiarrhythmic drug cibenzoline attenuates left ventricular pressure gradient and improves transmitral Doppler flow pattern in patients with hypertrophic cardiomyopathy caused by midventricular obstruction. Circ J 2005; 69: 940-945.
9. Hamada M, Shigematsu Y, Hara Y, Suzuki M, Ikeda S, Ohtsuka T, et al. Antiarrhythmic drug, cibenzoline, can directly improve the left ventricular diastolic function in patients with hypertrophic cardiomyopathy. Jpn Circ J 2001; 65: 531-538.
10. Hamada M, Shigematsu Y, Hiwada K, Hara Y, Ikeda S, Okayama H, et al. Response to "altered mitral flow pattern in patients with hypertrophic obstructive cardiomyopathy". Circulation 1998; 98: 2099.
11. Hahalis G, Alexopoulos D, Manolis AS. Altered mitral flow pattern in patients with hypertrophic obstructive cardiomyopathy. Circulation 1998; 98: 2098-2099.
12. Richardson P, Mckenna W, Bristow M, Maisch B, Mautner B, O'connell J, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology task force on the definition and classification of cardiomyopathies. Circulation 1996; 93: 841-842.
13. Hamada M, Kawakami H, Shigematsu Y, Minamino N, Kangawa K, Matsuo H, et al. Increased plasma levels of adrenomedullin in patients with hypertrophic cardiomyopathy: Its relation to endothelin-1, natriuretic peptides and noradrenaline. Clin Sci 1998; 94: 21-28.
14. Khoo KC, Szuna AJ, Colburn WA, Aogaichi K, Morganroth J, Brazzell RK. Single-dose pharmacokinetics and dose proportionality of oral cibenzoline. J Clin Pharmacol 1984; 24: 283-288.
15. Brazzell RK, Rees MMC, Khoo KC, Szuna AJ, Sandor D, Hannigan J. Age and cibenzoline disposition. Clin Pharmacol Ther 1984; 36: 613-619.
16. Gwathmey JK, Warren SE, Briggs GM, Copelas L, Feldman MD, Callahan M Jr, et al. Diastolic dysfunction in hypertrophic cardiomyopathy: Effect on active force generation during systole. J Clin Invest 1991; 87: 1023-1031.
17. 2+ inward current by the class I antiarrhythmic agent, cibenzoline. Br J Pharmacol 1986; 87: 705-711.
18. 2+: Implications of mutations causal for familial hypertrophic cardiomyopathy. Basic Res Cardiol 1997; 92: 63 - 74.
19. Molkentin JD, Lu J-R, Antos CL, Markham B, Richardson J, Robbins J, et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998; 93: 215-228.
20. Courtois M, Kovacs SJ Jr, Ludbrook PA. Transmitral pressure-flow velocity relation: Importance of regional pressure gradients in the left ventricle during diastole. Circulation 1988; 78: 661-671.
21. Braunwald E, Lambrew CT, Rockoff SD, Ross J Jr, Morrow AG. Idiopathic hypertrophic subaortic stenosis. I: A description of the disease based upon an analysis of 64 patients. Circulation 1964; 30(Suppl IV): IV-3-IV-119.
22. Kondo N, Sakurai K, Toyoda T, Yokoyama M, Daimon M, Hujimoto Y, et al. Cibenzoline relieves the pressure gradient of the left ventricular outflow tract stenosis with hypertrophic cardiomyopathy during bicycle ergometry. Shinzo 2001; 33: 841-846 (in Japanese).
23. Ommen SR, Maron BJ, Olivotto I, Maron MS, Cecchi F, Betocchi S, et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005; 46: 470-476.
24. Shamin W, Yousufuddin M, Wang D, Henein M, Seggewiss H, Flather M, et al. Nonsurgical reduction of the interventricular septum in patients with hypertrophic cardiomyopathy. N Engl J Med 2002; 347: 1326-1333.
25. Tsuchikane E, Takeda Y, Kobayashi T, Yachiku K, Nasu K, Kobayashi Y, et al. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy. Circ J 2003; 67: 763-767.
26. Cazes M, Chassaing C, Martinet M, Cloarec A, Provost D, Boucher M, et al. Comparison of anticholinergic effects of cibenzoline, disopyramide, and atropine. J Cardiovasc Pharmacol 1990; 15: 308-316.